These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice. Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925 [TBL] [Abstract][Full Text] [Related]
6. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. González-López TJ; Pascual C; Álvarez-Román MT; Fernández-Fuertes F; Sánchez-González B; Caparrós I; Jarque I; Mingot-Castellano ME; Hernández-Rivas JA; Martín-Salces M; Solán L; Beneit P; Jiménez R; Bernat S; Andrade MM; Cortés M; Cortti MJ; Pérez-Crespo S; Gómez-Núñez M; Olivera PE; Pérez-Rus G; Martínez-Robles V; Alonso R; Fernández-Rodríguez A; Arratibel MC; Perera M; Fernández-Miñano C; Fuertes-Palacio MA; Vázquez-Paganini JA; Gutierrez-Jomarrón I; Valcarce I; de Cabo E; Sainz A; Fisac R; Aguilar C; Paz Martínez-Badas M; Peñarrubia MJ; Calbacho M; de Cos C; González-Silva M; Coria E; Alonso A; Casaus A; Luaña A; Galán P; Fernández-Canal C; Garcia-Frade J; González-Porras JR Am J Hematol; 2015 Mar; 90(3):E40-3. PubMed ID: 25400215 [TBL] [Abstract][Full Text] [Related]
7. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice. González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819 [TBL] [Abstract][Full Text] [Related]
8. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484 [TBL] [Abstract][Full Text] [Related]
9. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP). Boyers D; Jia X; Crowther M; Jenkinson D; Fraser C; Mowatt G Health Technol Assess; 2011 May; 15 Suppl 1():23-32. PubMed ID: 21609650 [TBL] [Abstract][Full Text] [Related]
10. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. Yang R; Li J; Jin J; Huang M; Yu Z; Xu X; Zhang X; Hou M Br J Haematol; 2017 Jan; 176(1):101-110. PubMed ID: 27734464 [TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038 [TBL] [Abstract][Full Text] [Related]
12. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag. Tarantino MD; Fogarty PF; Shah P; Brainsky A Platelets; 2015; 26(1):93-6. PubMed ID: 24433306 [TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660 [TBL] [Abstract][Full Text] [Related]
15. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura. Zhang Y; Kolesar JM Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810 [TBL] [Abstract][Full Text] [Related]
16. An escalating treatment strategy for children with severe chronic immune thrombocytopenia: Preliminary report from a single center. Fu L; Ma J; Gu H; Ma J; Wei Y; Chen Z; Wu R Pediatr Blood Cancer; 2021 Jun; 68(6):e29006. PubMed ID: 33720524 [TBL] [Abstract][Full Text] [Related]
17. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. Al-Samkari H; Kuter DJ Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577 [No Abstract] [Full Text] [Related]
18. Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia. Wu K; Thapar M; Farrell C; Hayes S; Guo H; Hou M; Zhang J Clin Ther; 2015 Jul; 37(7):1382-95. PubMed ID: 25929594 [TBL] [Abstract][Full Text] [Related]
19. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632 [TBL] [Abstract][Full Text] [Related]